CA2231330A1 - Dosage a rendement eleve utilisant des proteines hybrides - Google Patents

Dosage a rendement eleve utilisant des proteines hybrides Download PDF

Info

Publication number
CA2231330A1
CA2231330A1 CA 2231330 CA2231330A CA2231330A1 CA 2231330 A1 CA2231330 A1 CA 2231330A1 CA 2231330 CA2231330 CA 2231330 CA 2231330 A CA2231330 A CA 2231330A CA 2231330 A1 CA2231330 A1 CA 2231330A1
Authority
CA
Canada
Prior art keywords
fusion protein
recited
protein
binding
expression vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2231330
Other languages
English (en)
Inventor
Alice Marcy
Scott P. Salowe
Douglas Wisniewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605210.5A external-priority patent/GB9605210D0/en
Application filed by Individual filed Critical Individual
Publication of CA2231330A1 publication Critical patent/CA2231330A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9493—Immunosupressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur un dosage à rendement élevé utilisé pour sélectionner des composés capables de se lier à une protéine hybride composée d'une protéine-cible et d'une protéine fixant FK506. L'invention concerne également le procédé de préparation de l'ADN codant la protéine hybride, et d'expression de cet ADN. L'invention se rapporte également aux séquences protéiques et d'ADN de recombinaison pour plusieurs protéines hybrides.
CA 2231330 1995-09-15 1996-09-11 Dosage a rendement eleve utilisant des proteines hybrides Abandoned CA2231330A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US381995P 1995-09-15 1995-09-15
US60/003,819 1995-09-15
GBGB9605210.5A GB9605210D0 (en) 1996-03-12 1996-03-12 A high throughput assay using fusion proteins
GB9605210.5 1996-03-12

Publications (1)

Publication Number Publication Date
CA2231330A1 true CA2231330A1 (fr) 1997-03-20

Family

ID=26308918

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2231330 Abandoned CA2231330A1 (fr) 1995-09-15 1996-09-11 Dosage a rendement eleve utilisant des proteines hybrides

Country Status (4)

Country Link
EP (1) EP0871648A1 (fr)
JP (1) JPH11513246A (fr)
CA (1) CA2231330A1 (fr)
WO (1) WO1997010253A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2250067A1 (fr) * 1996-04-18 1997-10-23 Ariad Pharmaceuticals, Inc. Dosage in vitro a polarisation de fluorescence
US6962982B2 (en) 2001-06-22 2005-11-08 Roche Diagnostics Corporation Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
US7094757B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
US20050130259A1 (en) * 2002-06-25 2005-06-16 Akira Ideno Expression vector, host, fused protein, process for producing fused protein and process for producing protein
EP1971684B1 (fr) 2006-01-03 2011-10-05 Roche Diagnostics GmbH Proteine de fusion chimerique d'activites chaperone et de repliement superieures
IL292387A (en) * 2019-10-23 2022-06-01 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis A chimeric polypeptide for immune cell regulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE187772T1 (de) * 1991-01-18 2000-01-15 Univ New York Cdns-klonierungsverfahren für rezeptortyrosinkinasezielprotein und hgrb- proteine
CA2054602C (fr) * 1991-10-31 2003-04-22 Anthony Pawson Methode de dosage d'une substance influant sur un systeme de regulation d'un ligand phosphoryle-sh2
US5498597A (en) * 1992-01-17 1996-03-12 Dana-Farber Cancer Institute, Inc. FKBP-13, an FK506-binding immunophilin
GB9210176D0 (en) * 1992-05-12 1992-06-24 Cemu Bioteknik Ab Chemical method
US5464745A (en) * 1993-03-31 1995-11-07 Novagen, Inc. Protein ligand binding region mapping system
US5580979A (en) * 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions

Also Published As

Publication number Publication date
JPH11513246A (ja) 1999-11-16
EP0871648A1 (fr) 1998-10-21
WO1997010253A1 (fr) 1997-03-20

Similar Documents

Publication Publication Date Title
Gagné et al. A proteomic approach to the identification of heterogeneous nuclear ribonucleoproteins as a new family of poly (ADP-ribose)-binding proteins
Iwabuchi et al. Two cellular proteins that bind to wild-type but not mutant p53.
Schaller et al. Autophosphorylation of the Focal Adhesion Kinase, ppl25FAK, Directs SH2-Dependent Binding of pp60 src
US5783398A (en) High throughput assay using fusion proteins
AU725477B2 (en) IKK-beta proteins, nucleic acids and methods
Phizicky et al. Protein-protein interactions: methods for detection and analysis
Warbrick et al. Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair
Thomas et al. The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin
Lamphere et al. Interaction between Cdc37 and Cdk4 in human cells
US9874567B2 (en) Kits to assay kinase activity
Andjelković et al. The catalytic subunit of protein phosphatase 2A associates with the translation termination factor eRF1.
US5776696A (en) High throughput assay using fusion proteins
EP1098967B1 (fr) Procede de detection d'interactions proteine-proteine et kit d'utilisation
Yeow-Fong et al. SNX9 as an adaptor for linking synaptojanin-1 to the Cdc42 effector ACK1
Becker et al. Expression of a tyrosine phosphorylated, DNA binding Stat3β dimer in bacteria
AU726294B2 (en) Ikk-alpha proteins, nucleic acids and methods
US7132278B2 (en) PAS kinase
CA2231330A1 (fr) Dosage a rendement eleve utilisant des proteines hybrides
WO1997010502A1 (fr) Dosage a rendement eleve utilisant des proteines de fusion
Kim et al. Modulation of EWS/WT1 activity by the v-Src protein tyrosine kinase
US5874230A (en) Assays using TRAF2-associated protein kinase polypeptides
WO1998056806A1 (fr) Proteine de coactivation de facteur de transcription, p/cip
US20050283003A1 (en) Reversible immobilization of arginine-tagged moieties on a silicate surface
WO1998041866A1 (fr) Dosage a haute capacite dans lequel des proteines de fusion sont utilisees
US20100029507A1 (en) The biochip for the detection of phosphorylation and the detection method using the same

Legal Events

Date Code Title Description
FZDE Dead